• 1
    Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996; 85: 291297.
  • 2
    Porte D, Jr. β-cells in type II diabetes mellitus. Diabetes 1991; 40: 166180.
  • 3
    Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994; 15: 516542.
  • 4
    Erbagci AB, Tarakcioglu M, Coskun Y, Sivasli E, Sibel NE. Mediators of inflammation in children with type I diabetes mellitus: Cytokines in type I diabetes children. Clin Biochem 2001; 34: 645650.DOI: 10.1016/S0009-9120(01)00275-2
  • 5
    Huerta MG, Nadler JL. Role of inflammatory pathways in the development and cardiovascular complications of type II diabetes. Curr Diab Rep 2002; 2: 396402.
  • 6
    Yang Z, Chen M, Wu R, McDuffie M, Nadler JL. The anti-inflammatory compound Lisofylline prevents type I diabetes in nonobese diabetic mice. Diabetologia 2002; 45: 13071314.DOI: 10.1007/s00125-002-0901-y
  • 7
    Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, Nadler JL. The novel anti-inflammatory compound, Lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice. Pancreas 2003; 26: e99e104.DOI: 10.1097/00006676-200305000-00021
  • 8
    Yang Z, Chen M, Ellett JD, Fialkow LB, Carter JD, Nadler JL. The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. Transplantation 2004; 77: 5560.DOI: 10.1097/01.TP.0000104844.48064.81
  • 9
    Chen M, Yang Z, Wu R, Nadler JL. Lisofylline, a novel anti-inflammatory agent, prevents pancreatic β-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism. Endocrinology 2001; 143: 23412348.
  • 10
    Gao Z, Konrad RJ, Collins H, Matschinsky FM, Rothenberg PL, Wolf BA. Wortmannin inhibits insulin secretion in pancreatic islets and β-TC3 cells independent of its inhibition of phosphatidylinositol 3-kinase. Diabetes 1996; 45: 854862.
  • 11
    Yang Z, Chen M, Ellett JD et al. Autoimmune diabetes is blocked in Stat4-deficient mice. J Autoimmun 2004; 22: 191200.DOI: 10.1016/j.jaut.2003.08.006
  • 12
    Prochazka M, Gaskins HR, Shultz LD, Leiter EH. The NOD-scid mouse: A model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci U S A 1992; 89: 32903294.
  • 13
    Colwell JA. Aspirin therapy in diabetes. Diabetes Care 1997; 20: 17671771.
  • 14
    Liang L, Beshay E, Prud'homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram prevents diabetes in NOD mice. Diabetes 1998; 47: 570575.
  • 15
    Ricordi C. Islet transplantation: A brave new world. Diabetes 2003; 52: 15951603.
  • 16
    Paraskevas S, Maysinger D, Wang R, Duguid WP, Rosenberg L. Cell loss in isolated human islets occurs by apoptosis. Pancreas 2000; 20: 270276.DOI: 10.1097/00006676-200004000-00008
  • 17
    Kurrer MO, Pakala SV, Hanson HL, Katz JD. β cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci U S A 1997; 94: 213218.DOI: 10.1073/pnas.94.1.213
  • 18
    Mauricio D, Mandrup-Poulsen T. Apoptosis and the pathogenesis of IDDM: A question of life and death. Diabetes 1998; 47: 15371543.
  • 19
    Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 13091312.DOI: 10.1126/science.281.5381.1309
  • 20
    Wollheim CB. β-cell mitochondria in the regulation of insulin secretion: A new culprit in type II diabetes. Diabetologia 2000; 43: 265277.DOI: 10.1007/s001250050044
  • 21
    Desagher S, Maryinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000; 10: 369377.DOI: 10.1016/S0962-8924(00)01803-1
  • 22
    Maechler P, Kennedy ED, Pozzan T, Wollheim CB. Mitochondrial activation directly triggers the exocytosis of insulin in permeabilized pancreatic β-cells. EMBO J 1997; 16: 38333841.DOI: 10.1093/emboj/16.13.3833
  • 23
    Chen M, Wu R, Yang Z, Nadler JL. Lisofylline inhibits Caspase 8 and protects INS-1 cell from TNF-α toxicity [Abstract]. Diabetes 2002; 51(Suppl 1): A384.
  • 24
    List AF, Maziarz R, Stiff P et al. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group. Bone Marrow Transplant 2000; 25: 283291.DOI: 10.1038/sj.bmt.1702114
  • 25
    Bursten SL, Federighi D, Wald J, Meengs B, Spickler W, Nudelman E. Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. J Pharmacol Experiment Ther 1998; 284: 337345.
  • 26
    Rice GC, Brown PA, Nelson RJ, Bianco JA, Singer JW, Bursten S. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci U S A 1994; 91: 38573861.
  • 27
    Van Furth AM, Verhard-Seijmonsbergen EM, Van Furth R, Langermans JAM. Effect of lisofylline and pentoxifylline in the bacterial-stimulated production of TNF-α, IL-1 β and IL-10 by human leucocytes. Immunology 1997; 91: 193196.DOI: 10.1046/j.1365-2567.1997.00252.x
  • 28
    Rice GC, Rosen J, Weeks R et al. CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock 1994; 1: 254266.
  • 29
    Oka Y, Hasegawa N, Nakayama M, Murphy GA, Sussman HH, Raffin TA. Selective downregulation of neutrophils by a phosphatidic acid generation inhibitor in a porcine sepsis model. J Surg Res 1999; 81: 147155.DOI: 10.1006/jsre.1998.5453
  • 30
    Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, Nadler JL. Inhibition of STAT4 activation by Lisofylline is associated with the protection of autoimmune diabetes. Ann N Y Acad Sci 2003; 1005: 409411.DOI: 10.1196/annals.1288.069
  • 31
    Bright JJ, Du C, Coon M, Sriram S, Klaus SJ. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: An effect of the novel anti-inflammatory drug Lisofylline. J Immunol 1998; 161: 70157022.
  • 32
    Thierfelder WE, Van Deursen JM, Yamamoto K et al. Requirement for STAT4 in interleukin-12-mediated response of natural killer and T cells. Nature 1996; 382: 171174.DOI: 10.1038/382171a0
  • 33
    Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in STAT4-deficient mice. Nature 1996; 382: 174178.DOI: 10.1038/382174a0
  • 34
    Yang Z, Chen M, Nadler JL. A commentary review. Lisofylline: A potential lead for the treatment of diabetes. Biochem Phamacol 2004; (in press).